Literature DB >> 19370783

Incidence and survival of stomach cancer in a high-risk population of Chile.

Katy Heise1, Enriqueta Bertran, Marcelo E Andia, Catterina Ferreccio.   

Abstract

AIM: To study the incidence and survival rate of stomach cancer (SC) and its associated factors in a high risk population in Chile.
METHODS: The population-based cancer registry of Valdivia, included in the International Agency for Research on Cancer system, covers 356 396 residents of Valdivia Province, Southern Chile. We studied all SC cases entered in this Registry during 1998-2002 (529 cases). Population data came from the Chilean census (2002). Standardized incidence rates per 100 000 inhabitants (SIR) using the world population, cumulative risk of developing cancer before age 75, and rate ratios by sex, age, ethnicity and social factors were estimated. Relative survival (Ederer II method) and age-standardized estimates (Brenner method) were calculated. Specific survival rates (Kaplan-Meier) were measured at 3 and 5 years and survival curves were analyzed with the Logrank and Breslow tests. Survival was studied in relation to demographics, clinical presentation, laboratory results and medical management of the cases. Those variables significantly associated with survival were later included in a Cox multivariate model.
RESULTS: Between 1998 and 2002, 529 primary gastric cancers occurred in Valdivia (crude incidence rate 29.2 per 100 000 inhabitants). Most cases were male (69.0%), residents of urban areas (57.5%) and Hispanic (83.2%), with a low education level (84.5% < 8 school years). SC SIR was higher in men than women (40.8 and 14.8 respectively, P < 0.001), risk factors were low education RR 4.4 (95% CI: 2.9-6.8) and 1.6, (95% CI: 1.1-2.1) for women and men respectively and Mapuche ethnicity only significant for women (RR 2.2, 95% CI: 1.2-3.7). Of all cases, 76.4% were histologically confirmed, 11.5% had a death certificate only (DCO), 56.1% were TNM stage IV; 445 cases (84.1%) were eligible for survival analysis, all completed five years follow-up; 42 remained alive, 392 died of SC and 11 died from other causes. Specific 5-year survival, excluding cases with DCO, was 10.6% (95% CI: 7.7-13.5); 5-year relative survival rate was 12.3% (95% CI: 9.1-16.1), men 10.9% (95% CI: 7.4-15.2) and women 16.1% (95% CI: 9.5-24.5). Five-year specific survival was higher for patients aged < 55 years (17.3%), with intestinal type of cancer (14.6%), without metastasis (22.2%), tumor size < 4 cm (60.0%), without lymphatic invasion (77.1%), only involvement of the mucous membrane (100%). Statistically significant independent prognostic factors were: TNM staging, diffuse type, metastasis, supraclavicular adenopathy, palpable tumor, and hepatitis or ascites.
CONCLUSION: Social determinants are the main risk factors for SC, but not for survival. An advanced clinical stage at consultation is the main cause of poor SC survival.

Entities:  

Mesh:

Year:  2009        PMID: 19370783      PMCID: PMC2670413          DOI: 10.3748/wjg.15.1854

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  26 in total

1.  Comparison of stomach cancer incidence and survival in four continents.

Authors:  A Verdecchia; A Mariotto; G Gatta; M T Bustamante-Teixeira; W Ajiki
Journal:  Eur J Cancer       Date:  2003-07       Impact factor: 9.162

2.  Dietary patterns and risk of gastric cancer: a case-control study in Uruguay.

Authors:  Eduardo De Stefani; Pelayo Correa; Paolo Boffetta; Hugo Deneo-Pellegrini; Alvaro L Ronco; María Mendilaharsu
Journal:  Gastric Cancer       Date:  2004       Impact factor: 7.370

3.  [Populational research of gastric cancer in digestive symptomatic patients, from 1996 to 2000].

Authors:  A Calvo Belmar; M Pruyas; E Nilsen; P Verdugo
Journal:  Rev Med Chil       Date:  2001-07       Impact factor: 0.553

4.  Long-term prognosis of gastric cancer in a European country: a population-based study in Florence (Italy). 10-year survival of cases diagnosed in 1985-1987.

Authors:  A Barchielli; A Amorosi; D Balzi; E Crocetti; G Nesi
Journal:  Eur J Cancer       Date:  2001-09       Impact factor: 9.162

5.  Helicobacter pylori, chronic atrophic gastritis, inactive aldehyde dehydrogenase-2, macrocytosis and multiple upper aerodigestive tract cancers and the risk for gastric cancer in alcoholic Japanese men.

Authors:  Akira Yokoyama; Tetsuji Yokoyama; Tai Omori; Sachio Matsushita; Takeshi Mizukami; Hisao Takahashi; Susumu Higuchi; Katsuya Maruyama; Hiromasa Ishii; Toshifumi Hibi
Journal:  J Gastroenterol Hepatol       Date:  2007-02       Impact factor: 4.029

Review 6.  The epidemiology of gastric cancer.

Authors:  David M Roder
Journal:  Gastric Cancer       Date:  2002       Impact factor: 7.370

7.  Alcohol dehydrogenase 3 and risk of esophageal and gastric adenocarcinomas.

Authors:  Mary Beth Terry; Marilie D Gammon; Fang Fang Zhang; Thomas L Vaughan; Wong-Ho Chow; Harvey A Risch; Janet B Schoenberg; Susan T Mayne; Janet L Stanford; A Brian West; Heidi Rotterdam; William J Blot; Joseph F Fraumeni; Regina M Santella
Journal:  Cancer Causes Control       Date:  2007-07-31       Impact factor: 2.506

8.  Chronic advanced gastric cancer: clinicopathologic analysis of survival data.

Authors:  Walter C MacDonald; David A Owen; Nhu Le
Journal:  Hum Pathol       Date:  2008-05       Impact factor: 3.466

9.  Pathology and prognosis of gastric carcinoma. Findings in 10,000 patients who underwent primary gastrectomy.

Authors:  K Nakamura; T Ueyama; T Yao; Z X Xuan; K Ambe; Y Adachi; Y Yakeishi; A Matsukuma; M Enjoji
Journal:  Cancer       Date:  1992-09-01       Impact factor: 6.860

10.  Differences in the pattern of presentation and treatment of proximal and distal gastric cancer: results of the 2001 gastric patient care evaluation.

Authors:  Neal W Wilkinson; James Howe; Greer Gay; Lina Patel-Parekh; Carol Scott-Conner; John Donohue
Journal:  Ann Surg Oncol       Date:  2008-04-05       Impact factor: 5.344

View more
  15 in total

1.  Omission of breakfast and risk of gastric cancer in Mexico.

Authors:  Monserrat Verdalet-Olmedo; Clara Luz Sampieri; Jaime Morales-Romero; Hilda Montero-L de Guevara; Alvaro Manuel Machorro-Castaño; Kenneth León-Córdoba
Journal:  World J Gastrointest Oncol       Date:  2012-11-15

2.  The PI3K/AKT/mTOR pathway is activated in gastric cancer with potential prognostic and predictive significance.

Authors:  Oscar Tapia; Ismael Riquelme; Pamela Leal; Alejandra Sandoval; Susana Aedo; Helga Weber; Pablo Letelier; Enrique Bellolio; Miguel Villaseca; Patricia Garcia; Juan Carlos Roa
Journal:  Virchows Arch       Date:  2014-05-21       Impact factor: 4.064

3.  Ethnicity and Health: Experience with an Urban Mapuche Health Program from the Perspective of Key Actors.

Authors:  Jame Rebolledo Sanhueza; Mónica Manríquez Hizaut; Cristian Lagos Fernández; Verónica Figueroa Huencho; José Miguel Gómez López
Journal:  J Racial Ethn Health Disparities       Date:  2019-11-15

4.  Laparoscopic resectional gastric bypass in patients with morbid obesity: experience on 112 consecutive patients.

Authors:  Italo Braghetto; Attila Csendes; Owen Korn; Luis Gutierrez; Luis Brunet; Enrique Lanzarini; Maher Mushle; Héctor Valladares; Jorge Rojas
Journal:  J Gastrointest Surg       Date:  2011-01       Impact factor: 3.452

5.  Preparation, characterization, and anticancer efficacy of novel cobalt oxide nanoparticles conjugated with thiosemicarbazide.

Authors:  Mahsa Jarestan; Kimia Khalatbari; Ayda Pouraei; Seyed Ataollah Sadat Shandiz; Sadaf Beigi; Mohammad Hedayati; Amitis Majlesi; Fatemeh Akbari; Ali Salehzadeh
Journal:  3 Biotech       Date:  2020-05-05       Impact factor: 2.406

6.  MicroRNA-144 functions as a tumor suppressor in gastric cancer by targeting cyclooxygenase-2.

Authors:  Qiang Yao; Anxin Gu; Zhuozhong Wang; Yingwei Xue
Journal:  Exp Ther Med       Date:  2018-01-17       Impact factor: 2.447

7.  Palliative first-line therapy with weekly high-dose 5-fluorouracil and sodium folinic acid as a 24-hour infusion (AIO regimen) combined with weekly irinotecan in patients with metastatic adenocarcinoma of the stomach or esophagogastric junction followed by secondary metastatic resection after downsizing.

Authors:  Kathrin Koucky; Axel Wein; Peter C Konturek; Heinz Albrecht; Udo Reulbach; Gudrun Männlein; Kerstin Wolff; Nicola Ostermeier; Dagmar Busse; Henriette Golcher; Claus Schildberg; Rolf Janka; Werner Hohenberger; Eckhart G Hahn; Jürgen Siebler; Markus F Neurath; Frank Boxberger
Journal:  Med Sci Monit       Date:  2011-05

Review 8.  A snapshot of cancer in Chile: analytical frameworks for developing a cancer policy.

Authors:  Jorge Jimenez de la Jara; Gabriel Bastias; Catterina Ferreccio; Cristian Moscoso; Sofia Sagues; Camilo Cid; Eduardo Bronstein; Cristian Herrera; Bruno Nervi; Alejandro Corvalan; Ethel V Velasquez; Pamela Gonzalez; Enrique Castellon; Eva Bustamante; Sergio Oñate; Eileen McNerney; Richard Sullivan; Gareth I Owen
Journal:  Biol Res       Date:  2015-01-26       Impact factor: 5.612

Review 9.  Cancer in indigenous people in Latin America and the Caribbean: a review.

Authors:  Suzanne P Moore; David Forman; Marion Piñeros; Sdenka M Fernández; Marceli de Oliveira Santos; Freddie Bray
Journal:  Cancer Med       Date:  2013-12-03       Impact factor: 4.452

10.  Long term follow up and retrospective study on 533 gastric cancer cases.

Authors:  Wei-Juan Zeng; Wen-Qin Hu; Lin-Wei Wang; Shu-Guang Yan; Jian-Ding Li; Hao-Liang Zhao; Chun-Wei Peng; Gui-Fang Yang; Yan Li
Journal:  BMC Surg       Date:  2014-05-16       Impact factor: 2.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.